Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
11 participants
INTERVENTIONAL
2017-12-15
2019-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Efficacy and Long Term Effects of Transcranial Direct Current Stimulation (tDCS) in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
NCT04704687
Home-Based tDCS in Children With ADHD: A Randomized, Sham-Controlled tDCS and fNIRS Study
NCT04634006
The Effects of Methylphenidate and Non-invasive Brain Stimulation on Inhibitory Control in Children With ADHD
NCT04964427
An Study of Transcranial Direct Current Stimulation in Adults With ADHD
NCT02640651
Role of Transcranial Direct Current Stimulation (tDCS) in Patients With Attention Deficit Hyperactivity Disorder (ADHD)
NCT02580890
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In the last decade, transcranial direct current stimulation (tDCS) has received a surge of interest in clinical research since it could modulate cortical excitability and induce plasticity in human brain. The device sends a constant low direct current (e.g. 1-2 mA) delivered to the area of interest through the electrodes. This induces shifts in neuronal resting membrane potential changing cortical excitability. Based on the polarity-specific effects, anodal tDCS increases cortical excitability and cathodal tDCS decreases cortical excitability. To change the cortical excitability, tDCS differs from other brain stimulation techniques such as transcranial magnetic stimulation (TMS) in that it does not cause action potentials in cortical neurons, but rather induces shifts in neuronal resting membrane potential. This is considered to induce a lesser or no risk of a seizure. Given its advantages such as painlessness, safety, easiness to use, and low-cost, a number of tDCS studies has been increasing in the last decade particularly in motor rehabilitation and neuropsychiatric disorders such as depression, autism and schizophrenia with a positive and safety reports in adult and pediatric populations. Possible after-effect of tDCS has been also reported in motor and psychological disorders that opens a way to use tDCS as a therapeutic tool.
The most accepted theory of neural basis of ADHD is deficient of inhibitory control resulting in executive dysfunction. Inhibitory control or response inhibition is key feature of self-control and can be defined as ability to inhibit prepotent actions. Several evidences reveal a physiological association between the prefrontal cortex and its subcortical connection with the pathophysiology of ADHD. Neuroimaging studies demonstrate that regions of the right dorso-lateral prefrontal cortex (DLPFC) play a role in the inhibition of motor response. During preforming an inhibitory task that is usually used to evaluate the efficiency of response inhibition such as stop-signal and go/no-go tasks, this area become active in healthy individual, while in ADHD showed hypo-activation compared to control.
Evidences showed that the task performance in stop-signal and go/no-go tasks can be influenced by tDCS application to the DLPFC in healthy subjects. It was recently reported that a single session of cathodal tDCS, using a single session of 1.5 mA for 15 minutes over the left DLPFC improved their ability to inhibit themselves by do not response to no-go stimulus during go/no-go tasks compared to anodal and sham conditions in adolescents with ADHD. It was postulated that the inter-hemispheric inhibition (IHI) between two regions (left and right DLPFC) might play a role in this finding. Based on the possibility that cathodal stimulation decreases excitability and thus IHI drive from the left DLPFC is decreased, facilitating activity of the right DLPFC where is involved in inhibition of motor response as demonstrated by neuroimaging studies. Using a single session of oscillatory tDCS during early sleep, memory consolidation and reaction times in a go/no-go task were improved on the next day in children with ADHD. This is an argument to explore its possible therapeutic effect in long-term use. Five tDCS sessions for five consecutive days was reported to be safe and improves aspect of attention in children and adolescents with ADHD, however, its after-effect in this population is unknown. In patients with depressive disorder, multiple sessions of tDCS over the left DLPFC for five or ten days has been demonstrated to decrease depressive symptoms and lasted for a month. It was reported in patient with depressive disorder that after five days of tDCS sessions on alternative day did not show an improvement, positive results was observed after 10 days. This suggests that a longer observation period is probably required to detect a true tDCS effect.
The use of electrophysiological techniques, especially of event-related potentials (ERP) measured by means of electroencephalography (EEG) allows for analysis of neural change accompanying inhibitory process in the brain. Two ERP components, the no-go N2 and P3 that are the most commonly studied in go/no-go tasks have been linked to response conflict and response inhibition. Studies have reported lower N2 and P3 amplitudes during go/no-go tasks in children and adolescents with ADHD.
To expand current information on tDCS as an emerging treatment for ADHD patients, in this study, investigators will investigate the effectiveness of multiple sessions of cathodal tDCS over the left DLPFC on inhibitory control in children and adolescents with ADHD. tDCS (cathodal/sham) will be applied every day for five consecutive days. Behavioral and neurophysiological parameters using an inhibitory task (go/no-go tasks) and the no-go N2 and P3 ERP components will be measured before tDCS, immediately after 5 sessions of tDCS, one week later, and one month after treatment onset.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active tDCS
Cathodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the anode will be placed over the right supraorbital (Fp2), using rectangular saline-soaked sponge pads 35 cm2. The current intensity of 1.5 mA will be used for 15 mins for a session.
tDCS
Five sessions (active/sham) will be held on five consecutive days. The parameter of electrode size, current strength and current duration were previously tested for safety in children
Sham tDCS
Cathodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the anode will be placed over the right supraorbital (Fp2), using rectangular saline-soaked sponge pads 35 cm2. The current intensity of 1.5 mA will flow continuously only 120 seconds. The electrode will be attached until the end of stimulation even the current flows only at the beginning.
tDCS
Five sessions (active/sham) will be held on five consecutive days. The parameter of electrode size, current strength and current duration were previously tested for safety in children
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tDCS
Five sessions (active/sham) will be held on five consecutive days. The parameter of electrode size, current strength and current duration were previously tested for safety in children
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Right-handed
3. Free of any neurological antecedent, unstable medical conditions such as epilepsy; although tDCS is believed to induce very less or no risk of seizure and epileptic seizure have never been reported in tDCS study even in a study with active epilepsy.
Exclusion Criteria
2. No clear neurological antecedent history
3. Presence of intracranial metal implantation, cochlea implant, or cardiac pacemaker
4. Motor or perceptual handicap that would prevent using the computer program
5. For patients who under medication, poor-adjusted to their medication, type and dosage of medication is changed less than 4 weeks prior to the start
6. Subjects are participating in the other protocol or receiving alternative treatment such transcranial magnetic stimulation.
7 Years
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mahidol University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wanalee Klomjai, PhD
Role: PRINCIPAL_INVESTIGATOR
Mahidol University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty ofPhysical Therapy, Mahidol University
Salaya, Nakonpathom, Thailand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Klomjai W, Siripornpanich V, Aneksan B, Vimolratana O, Permpoonputtana K, Tretriluxana J, Thichanpiang P. Effects of cathodal transcranial direct current stimulation on inhibitory and attention control in children and adolescents with attention-deficit hyperactivity disorder: A pilot randomized sham-controlled crossover study. J Psychiatr Res. 2022 Jun;150:130-141. doi: 10.1016/j.jpsychires.2022.02.032. Epub 2022 Mar 2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MU-IRB 2017/046.2002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.